a Molecular Entomology Laboratory, Department of Biotechnology , Periyar University , Salem , Tamil Nadu , India.
Artif Cells Nanomed Biotechnol. 2017 Dec;45(8):1490-1495. doi: 10.1080/21691401.2016.1252383. Epub 2016 Nov 10.
Mosquitoes are major vectors for the transmission of many diseases like chikungunya, malaria, dengue, zika, etc. worldwide. In the present study, selenium nanoparticles (SeNPs) were synthesized from Clausena dentata and were tested for their larvicidal efficacy against the fourth-instar larvae of Anopheles stephensi, Aedes Aegypti, and Culex quinquefasciatus. The synthesized nanoparticles were characterized using UV-Vis spectroscopy, Fourier Transform Infrared Radiation (FTIR) spectroscopy, EDaX, and SEM. The results recorded from UV-Vis spectroscopy show the peak absorption spectrum at 420 nm. In FTIR, the maximum peak value is 2922.25 cm assigned to N-H group (amide group). In EDaX analysis shows peak around 72.64 which confirm the binding intensity of selenium. In SEM analysis, the synthesized SeNPs sizes were ranging from 46.32 nm to 78.88 nm. The synthesized SeNPs produced high mortality with very low concentration (LC) were 240.714 mg/L; 104.13 mg/L, and 99.602 mg/L for A. stephensi, A. Aegypti, and C. quinquefasciatus, respectively. These results suggest that the C. dentata leaf extract-mediated biosynthesis of SeNPs has the potential to be used as an ideal ecofriendly approach toward the control of mosquito vectors at early stages.
蚊子是许多疾病(如基孔肯雅热、疟疾、登革热、寨卡等)的主要传播媒介。在本研究中,从枳椇中合成了硒纳米颗粒(SeNPs),并测试了它们对第四龄期的致倦库蚊、埃及伊蚊和淡色库蚊幼虫的杀幼虫效果。合成的纳米颗粒使用紫外可见分光光度法、傅里叶变换红外辐射(FTIR)光谱、EDaX 和 SEM 进行了表征。从紫外可见光谱记录的结果显示出 420nm 的最大吸收峰。在 FTIR 中,最大峰值为 2922.25cm,分配给 N-H 组(酰胺组)。在 EDaX 分析中,周围的峰值为 72.64,证实了硒的结合强度。在 SEM 分析中,合成的 SeNPs 尺寸范围为 46.32nm 至 78.88nm。合成的 SeNPs 以非常低的浓度(LC)产生了高死亡率,分别为 240.714mg/L;104.13mg/L 和 99.602mg/L,用于致倦库蚊、埃及伊蚊和淡色库蚊。这些结果表明,枳椇叶提取物介导的 SeNPs 合成具有作为早期控制蚊子传播媒介的理想环保方法的潜力。
Artif Cells Nanomed Biotechnol. 2016-11-10
Nanomaterials (Basel). 2025-2-16
Biol Trace Elem Res. 2024-10-24
Health Care Sci. 2024-8-13
Front Pharmacol. 2024-8-9
Front Microbiol. 2024-5-20